Marker Therapeutics (MRKR) Misses Q3 EPS by 12c

Marker Therapeutics (NASDAQ: MRKR) reported Q3 EPS of ($0.12). Revenue for the quarter came in at $1.23 million.

For earnings history and earnings-related data on Marker Therapeutics (MRKR) click here.

You May Also Be Interested In

• Anthropic plans IPO potentially exceeding SpaceX's $86B record - Bloomberg
• Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
• Walmart (WMT) Tops Q2 EPS by 7c, Beats on Revenue; Offers FY27 EPS Guidance